[Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma].
OBJECTIVE
To investigate the relationship between the serum half life of CA(125) and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma treated with neoadjuvant chemotherapy.


METHODS
Clinical data of 39 patients who had undergone neoadjuvant chemotherapy were analyzed retrospectively. Patients were divided into two groups according to the serum half-life of CA(125), and the optimal operation rate and prognosis were compared.


RESULTS
The optimal operation rate in patients with serum half-life >or= 20 days was significantly lower than that in patients with serum half-life < 20 days (29% vs 80%, P < 0.01). Cumulative survival was higher in patients with serum half-life < 20 days (P < 0.01). Serum half-life of CA(125) and tumor residual after operation were independent prognostic factors by COX model analysis.


CONCLUSIONS
Serum half-life of CA(125) may indicate optimal debulking operation, and it is an independent prognostic factor in ovarian carcinoma patients treated with neoadjuvant chemotherapy.
Xi
Xiao-wei
XW
Department of Obstetrics and Gynecology, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China.
Wan
Xiao-ping
XP
Li
Shuang-di
SD
Sun
Ting-wei
TW
Zhu
Ya-ping
YP
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006207:Half-Life; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
D018394:CA-125 Antigen; D002945:Cisplatin